XBiotech Inc.
XBIT
$7.87
-$0.34-4.14%
| Weiss Ratings | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.12 | |||
| Price History | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.47% | |||
| 30-Day Total Return | 24.37% | |||
| 60-Day Total Return | 72.33% | |||
| 90-Day Total Return | 70.11% | |||
| Year to Date Total Return | 82.26% | |||
| 1-Year Total Return | 158.50% | |||
| 2-Year Total Return | 9.10% | |||
| 3-Year Total Return | -63.57% | |||
| 5-Year Total Return | -19.43% | |||
| 52-Week High % Change | -17.57% | |||
| 52-Week Low % Change | 169.18% | |||
| Price | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.96 | |||
| 52-Week Low Price | $3.05 | |||
| 52-Week Low Price (Date) | Apr 26, 2023 | |||
| 52-Week High Price (Date) | Apr 10, 2024 | |||
| Valuation | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 244.83M | |||
| Enterprise Value | 44.80M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.81 | |||
| Earnings Per Share Growth | -25.05% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.12 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $7.91 | |||
| Enterprise Value/EBITDA (TTM) | -1.40 | |||
| Enterprise Value/EBIT | -1.33 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 30.44M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | $2.50 | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | $2.50 | |||
| Company Info | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 512 386 2900 | |||
| Address | 5217 Winnebago Lane Austin, TX 78744 | |||
| Website | www.xbiotech.com | |||
| Country | United States | |||
| Year Founded | 2005 | |||
| Profitability | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -9.92% | |||
| Return on Equity | -- | |||
| Income Statement | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -35.77M | |||
| EBIT (TTM) | -37.51M | |||
| Net Income (TTM) | -24.56M | |||
| Net Income Avl. to Common (TTM) | -24.56M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -44.71% | |||
| EPS Diluted (TTM) | -0.81 | |||
| EPS Diluted Growth (Q YOY) | -47.81% | |||
| Balance Sheet | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 200.02M | |||
| Cash Per Share (Q) | $6.57 | |||
| Total Current Assets (Q) | 201.72M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 218.85M | |||
| Current Ratio (Q) | 33.069 | |||
| Book Value Per Share (Q) | $7.19 | |||
| Total Assets (Q) | 226.62M | |||
| Total Current Liabilities (Q) | 6.10M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 7.77M | |||
| Total Common Equity (Q) | 218.85M | |||
| Cash Flow | XBIT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 61.50M | |||
| Cash from Financing (TTM) | -9.00K | |||
| Net Change in Cash (TTM) | 42.72M | |||
| Levered Free Cash Flow (TTM) | -16.10M | |||
| Cash from Operations (TTM) | -18.73M | |||
